Fiasp® can be administered in a variety of ways
Prefilled pen, durable pen with a cartridge, vial and syringe, and an insulin pump
Refer to the insulin infusion pump user manual to see if Fiasp® can be used. Use in accordance with the insulin pump’s instructions for use.
The Fiasp® FlexTouch® Pen
No push-button extension
No matter what dose is dialed, the Fiasp® FlexTouch® push button doesn’t extend
Dosing from 1-80 units2,3
Patients may hear or feel a click when the FlexTouch® dose is delivereda,b
aAfter the dose display has returned to 0, the needle should be kept under the skin for at least 6 seconds to ensure the full dose is delivered. Refer to complete Instructions For Use on how to properly administer your patients’ insulin.
bUse Fiasp® FlexTouch® pen with caution in patients with visual impairment that may rely on audible clicks to dial their dose.
Fiasp® FlexTouch® pen instructions
Follow the illustrated step-by-step Instructions For Use for Fiasp® FlexTouch®. Patients can view this video on MyFiasp.com
Novo Nordisk offers patient support, including resources detailing how to administer Fiasp®
10-mL vial
For administration by syringe, by IV infusion, or through an insulin pump
Allows for half-unit dosing1
Omnipod® is cleared for use with Fiasp®
The Omnipod® holds up to 200 units for up to 3 daysc of nonstop insulin delivery. The discreet, tubeless, waterproofd Pod can be worn almost anywhere your patients would inject Fiasp®.
c72 hours of continuous insulin delivery.
dThe Pod has an IP28 rating for up to 25 feet for 60 minutes. The Personal Diabetes Manager is not waterproof.
PenFill® cartridge
Designed for use with durable insulin delivery devices, such as NovoPen Echo®
Allows for half-unit dosing4
Lower environmental impact compared to prefilled disposable insulin pens
Fiasp® PenFill® is approved for use with NovoPen Echo®
Durable pen that lasts up to 5 years
More precise half-unit dosing
Automatically records the last dose and approximate time since the last injection4
A separate prescription is required for NovoPen Echo®, Fiasp® PenFill®, and needles. Needles are sold separately and need to be processed by a pharmacist.
NovoPen Echo® instructions
Follow the illustrated step-by-step Instructions For Use for NovoPen Echo®. Patients can view this video on MyFiasp.com
Patients with commercial insurance may be eligible to pay as little as $0 for their NovoPen Echo® with a savings card.e Direct patients to NovoPenEchoSavings.com to get their savings card.
How to store Fiasp®
Fiasp® FlexTouch®
Not in use (unopened): If unopened, Fiasp® FlexTouch® should be stored in a refrigerator (36°F to 46°F [2°C to 8°C]) until expiration date. If unopened but stored outside of refrigerated conditions, begin in-use storage for a maximum of 4 weeks.1
In use (opened): After first use, Fiasp® FlexTouch® can be stored at room temperature (below 86°F [30°C]) or in the refrigerator (36°F to 46°F [2°C to 8°C]) without the needle attached for a maximum of 4 weeks (28 days).1
Fiasp® vial
Not in use (unopened): If unopened, Fiasp® vials should be stored in a refrigerator (36°F to 46°F [2°C to 8°C]) until expiration date. If unopened but stored outside of refrigerated conditions, begin in-use storage for a maximum of 4 weeks.1
In use (opened): After first use, Fiasp® vials can be stored at room temperature (below 86°F [30°C]) or in the refrigerator (36°F to 46°F [2°C to 8°C]) for a maximum of 4 weeks (28 days).1
Fiasp® PenFill®
Not in use (unopened): If unopened, Fiasp® PenFill® should be stored in a refrigerator (36°F to 46°F [2°C to 8°C]) until expiration date. If unopened but stored outside of refrigerated conditions, begin in-use storage for a maximum of 4 weeks.1
In use (opened): After first use, Fiasp® PenFill® can be stored at room temperature (below 86°F [30°C]) for a maximum of 4 weeks (28 days).1 Do not refrigerate Fiasp® PenFill® cartridges after first use.
Get your appropriate patients started on Fiasp® with samples
Indications and Usage for Fiasp® (insulin aspart injection) 100 U/mL
Fiasp® (insulin aspart injection) 100 U/mL is a rapid-acting insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Important Safety Information
Contraindications
- Fiasp® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Fiasp® or one of its excipients.
Warnings and Precautions
- Never share a Fiasp® FlexTouch® Pen, PenFill® cartridge or PenFill® cartridge device between patients, even if the needle is changed. Patients using Fiasp® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
- Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
- Hypoglycemia is the most common adverse reaction of insulin, including Fiasp®, and may be life-threatening. Increase glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness.
- To avoid medication errors and accidental mix-ups between Fiasp® and other insulin products, instruct patients to always check the insulin label before injection.
- As with all insulins, Fiasp® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
- Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including Fiasp®.
- Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Fiasp®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered.
- Pump or infusion set malfunctions can lead to a rapid onset of hyperglycemia and ketoacidosis. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Interim therapy with subcutaneous injection of Fiasp® may be required. Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.
Adverse Reactions
- Adverse reactions observed with Fiasp® include hypoglycemia, allergic reactions, hypersensitivity, injection site reactions, lipodystrophy, and weight gain.
Use in Specific Populations
- Pediatric patients with type 1 diabetes treated with mealtime and postmeal Fiasp® reported a higher rate of blood glucose confirmed hypoglycemic episodes compared to patients treated with NovoLog® (insulin aspart injection); the imbalance was greater during the nocturnal period. Monitor blood glucose levels closely in pediatric patients.
- Like all insulins, Fiasp® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments.
Please click here for Fiasp® Prescribing Information.
The Omnipod DASH® Insulin Management System Important Safety Information
The Omnipod DASH® Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. Additionally, the Omnipod DASH® System is interoperable with a compatible blood glucose meter to receive and display blood glucose measurements. The Omnipod DASH® System has been tested and found to be safe for use with the following U-100 insulin: NovoLog® (insulin aspart) injection 100 U/mL, Humalog®, Apidra®, Fiasp® or Admelog®. Refer to the Omnipod DASH® Insulin Management System User Guide for complete safety information, including indications, contraindications, warnings, cautions, and instructions.
References:
- Fiasp [package insert]. Plainsboro, NJ: Novo Nordisk Inc; December 2019.
- Wielandt JO, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. An assessment of dose accuracy and injection force of a novel prefilled insulin pen: comparison with a widely used prefilled insulin pen. Expert Opin Drug Deliv. 2011;8(10):1271-1276.
- Wielandt JO, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. FlexTouch: a prefilled insulin pen with a novel injection mechanism with consistent high accuracy at low- (1 U), medium- (40 U), and high- (80 U) dose settings. J Diabetes Sci Technol. 2011;5(5):1195-1199.
- NovoPen Echo. User guide. Plainsboro, NJ: Novo Nordisk Inc; 2018.